Fecal microbiome signatures of pancreatic cancer patients/Experiment 3

From BugSigDB


Reviewed Marked as Reviewed by Claregrieve1 on 2022/12/30

Curated date: 2021/02/04

Curator: Yu Wang

Revision editor(s): WikiWorks, Fatima, Yu Wang, Claregrieve1, Victoria

Subjects

Location of subjects
Israel
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Pancreatic carcinoma cancer of pancreas,cancer of the pancreas,carcinoma of exocrine pancreas,carcinoma of pancreas,carcinoma of the pancreas,exocrine cancer,exocrine pancreas carcinoma,exocrine pancreatic carcinoma,pancreas cancer,pancreas carcinoma,pancreatic cancer,pancreatic cancer (not islets),pancreatic carcinoma,pancreatic carcinoma, familial,Pancreatic carcinoma
Group 0 name Corresponds to the control (unexposed) group for case-control studies
NBO PC
Group 1 name Corresponds to the case (exposed) group for case-control studies
BO PC
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Bile duct-obstructed pancreatic cancer patients.
Group 0 sample size Number of subjects in the control (unexposed) group
16
Group 1 sample size Number of subjects in the case (exposed) group
11
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
Individuals who were exposed to antibiotics up to 8 weeks before sampling were excluded from the analysis.

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
Not specified
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
LEfSe
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
No
LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
3

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
unchanged

Signature 1

Reviewed Marked as Reviewed by Claregrieve1 on 2022/12/30

Curated date: 2021/02/04

Curator: Yu Wang

Revision editor(s): Fatima, Yu Wang

Source: Figure 3b

Description: Taxa identified by LEfSe as differentiating between BO PC and NBO PC patients.

Abundance in Group 1: decreased abundance in BO PC

NCBI Quality ControlLinks
Blautia

Revision editor(s): Fatima, Yu Wang

Signature 2

Reviewed Marked as Reviewed by Claregrieve1 on 2022/12/30

Curated date: 2021/02/04

Curator: Yu Wang

Revision editor(s): Fatima, Yu Wang, Claregrieve1

Source: Figure 3b

Description: Taxa identified by LEfSe as differentiating between BO PC and NBO PC patients.

Abundance in Group 1: increased abundance in BO PC

NCBI Quality ControlLinks
Selenomonadales
Veillonellaceae
Prevotella

Revision editor(s): Fatima, Yu Wang, Claregrieve1